https://www.ibstreatmentcenter.com/Articles/ROMEIIIFBDpaper.pdf

Functional Bowel Disorders

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(06)68880-6.pdf

Mild cognitive impairment

https://www.ualberta.ca/~loewen/Medicine/GIM%20Residents%20Core%20Reading/IBD,%20CROHN'S%20AND%20U.C/accent%20i%20trial.pdf

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Objective. —To determine the risk of elevated total homocysteine (tHcy) levels for arteriosclerotic vascular disease, estimate the reduction of tHcy by folic acid, and calculate the potential reduction of coronary artery disease (CAD) mortality by increasing folic acid intake. Data Sources. —MEDLINE search for meta-analysis of 27 studies relating homocysteine to arteriosclerotic vascular disease and 11 studies of folic acid effects on tHcy levels. Study Selection and Data Extraction. —Studies dealing with CAD, cerebrovascular disease, and peripheral arterial vascular disease were selected. Three prospective and six population-based case-control studies were considered of high quality. Five cross-sectional and 13 other case-control studies were also included. Causality of tHcy's role in the pathogenesis of vascular disease was inferred because of consistency across studies by different investigators using different methods in different populations. Data Synthesis. —Elevations in tHcy were considered an independent graded risk factor for arteriosclerotic vascular diseases. The odds ratio (OR) for CAD of a 5-μmol/L tHcy increment is 1.6(95% confidence interval [Cl], 1.4 to 1.7) for men and 1.8 (95% Cl, 1.3 to 1.9) for women. A total of 10% of the population's CAD risk appears attributable to tHcy. The OR for cerebrovascular disease (5-μmol/L tHcy increment) is 1.5 (95% Cl, 1.3 to 1.9). Peripheral arterial disease also showed a strong association. Increased folic acid intake (approximately 200 μg/d) reduces tHcy levels by approximately 4 μmol/L. Assuming that lower tHcy levels decrease CAD mortality, we calculated the effect of (1) increased dietary folate, (2) supplementation by tablets, and (3) grain fortification. Under different assumptions, 13 500 to 50 000 CAD deaths annually could be avoided; fortification of food had the largest impact. Conclusions. —A 5-μmol/L tHcy increment elevates CAD risk by as much as cholesterol increases of 0.5 mmol/L (20 mg/dL). Higher folic acid intake by reducing tHcy levels promises to prevent arteriosclerotic vascular disease. Clinical trials are urgently needed. Concerns about masking cobalamin deficiency by folic acid could be lessened by adding 1 mg of cobalamin to folic acid supplements. ( JAMA . 1995;274:1049-1057)

https://jamanetwork.com/journals/jama/articlepdf/389728/jama_274_13_028.pdf

A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes

https://www.gastrojournal.org/article/S0016-5085(97)70025-8/pdf

Prevalence and clinical spectrum of gastroesophageal reflux : a population-based study in Olmsted County, Minnesota

https://www.gastrojournal.org/article/S0016-5085(01)92039-6/pdf

The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

https://www.gastrojournal.org/article/S0016-5085(02)12641-2/pdf

The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota.

https://www.gastrojournal.org/article/S0016-5085(01)71195-X/pdf

Alan R. Zinsmeister

Papers

Prevalence and clinical spectrum of gastroesophageal reflux : a population-based study in Olmsted County, Minnesota

The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota.

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.